Assembly Biosciences Inc Dossier
Qualitative Analysis
Business overview
Assembly Biosciences, Inc. (Nasdaq: ASMB) is a clinical-stage biotechnology company dedicated to developing innovative, small-molecule therapeutics targeting serious viral diseases. The company's pipeline focuses on addressing significant unmet needs in recurrent genital herpes (HSV), chronic hepatitis B virus (HBV), and chronic hepatitis delta virus (HDV) infections. Assembly Bio's strategic approach leverages its deep virology expertise and a robust, multi-year collaboration with Gilead Sciences, Inc. to co-develop and commercialize high-potential antiviral candidates. Its lead programs include long-acting helicase-primase inhibitors (HPI) for HSV and orally bioavailable entry inhibitors targeting the NTCP receptor for HDV.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the clinical development of oral entry inhibitor candidate ABI-6250 into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), following a constructive pre-IND meeting with the FDA.
Expected impact: Broadens the addressable patient population and therapeutic indications for the company's lead wholly owned asset.
Actively seeking external development partners for ABI-4334, a next-generation capsid assembly modulator targeting chronic hepatitis B virus (HBV), after Gilead declined to exercise its opt-in license option.
Expected impact: Allows Assembly Bio to advance its HBV portfolio without bearing the full financial burden of clinical development.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
A 12-year collaboration established in October 2023 to develop antiviral therapies. In December 2025, Gilead exercised its option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs (ABI-1179 and ABI-5366).
Terms: Assembly Bio received a $100 million upfront payment in 2023 (including a $15.2 million equity investment). For the HSV program license in December 2025, Assembly Bio received a $35 million net option fee (reflecting a $45 million option fee net of $10 million in accelerated funding). Assembly Bio remains eligible for up to $330 million in regulatory and commercial milestones, plus tiered royalties.